Page 53 - 2019_07 resto del Mondo-web

RSV in HCT and hematologic malignancies
(HCT) recipients. BMT Tandem Meeting, Salt Lake City, UT, USA; February 21-25, 2018. Presentation LBA 6.
100.Chemaly RFD, Sanjeet S, Bergeron A, et al. A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir(GS- 5806), an oral fusion inhibitor for the treat- ment of respiratory syncytial virus (RSV) upper respiratory tract infection (URTI) in hematopoietic-cell transplant (HCT) recipi- ents. BMT Tandem Meeting, Salt Lake City, UT, USA; February 21-25, 2018.
Presentation LBA 7.
101. Jalal H, Bibby DF, Bennett J, et al. Molecular
investigations of an outbreak of parainfluen- za virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol. 2007;45(6):1690-1696.
102.Lehners N, Schnitzler P, Geis S, et al. Risk factors and containment of respiratory syn- cytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant. 2013;48(12):1548-1553.
103. Gala CL, Hall CB, Schnabel KC, et al. The
use of eye-nose goggles to control nosoco- mial respiratory syncytial virus infection. JAMA. 1986;256(19):2706-2708.
104.Krasinski K, LaCouture R, Holzman RS, Waithe E, Bonk S, Hanna B. Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosoco- mial transmission. J Pediatr. 1990;116(6): 894-898.
105.Ariza-Heredia EJ, Chemaly RF. Update on infection control practices in cancer hospi- tals. CA Cancer J Clin. 2018;68(5):340-355.
haematologica | 2019; 104(7)
1331